Cellular Mechanisms of Vasoregulation by Volatile Anesthetics

挥发性麻醉剂血管调节的细胞机制

• 批准号: 7936528
• 负责人: Rostislav Bychkov
• 金额: $ 13.06万
• 依托单位: UNIVERSIDAD CENTRAL DEL CARIBE
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-08-01 至 2013-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7936528
• 关键词: American Heart Association; Anesthetics; Antidepressive Agents; Aorta; Area; Arteries; Astrocytes; Biology; Blood - brain barrier anatomy; Blood Circulation; Blood Pressure; Blood Vessels; Brain; Caliber; Cardiopulmonary Bypass; Cardiovascular Diseases; Carotid Endarterectomy; Cause of Death; Cell physiology; Cells; Cerebral Aneurysm; Cerebral Ischemia; Cerebrovascular Circulation; Cerebrum; Chlorpromazine; Clip; Coronary artery; Data; Development; Development Plans; Disease; Educational process of instructing; Electrophysiology (science); Endothelial Cells; Environment; Family; Fluoxetine; General Anesthesia; General anesthetic drugs; Goals; Halothane; Heart; Human; Hypertension; Image; Imaging Techniques; Inhalation Anesthetics; Injury; Investigation; Ischemic Stroke; Lead; Local Anesthetics; Lung; Measurement; Mechanics; Mediating; Medical; Medical Students; Membrane Potentials; Mental Depression; Mentors; Mesenteric Arteries; Mesentery; Methods; Microcirculation; Muscle Cells; Myocardial Ischemia; Neuronal Injury; Neurons; Neuroprotective Agents; Neurosciences; Nitrous Oxide; Operative Surgical Procedures; Organ; Pathologic; Pathway interactions; Pharmaceutical Preparations; Pharmacology; Physiological; Positioning Attribute; Potassium Channel; Probability; Procedures; Proteins; Pulmonary artery structure; Purinoceptor; Reactive Oxygen Species; Reporting; Research; Research Design; Research Personnel; Resistance; Rest; Riluzole; Role; Signal Pathway; Signal Transduction; Smooth Muscle Myocytes; Societies; Stroke; Students; Testing; Therapeutic; Thoracic aorta; Tissues; Treatment Protocols; United States National Institutes of Health; Universities; Vasodilation; Whole-Cell Recordings; Work; Xenon; cerebral artery; channel blockers; conditioning; high risk; hypertension treatment; independency; interest; lectures; meetings; member; middle cerebral artery; nerve supply; novel; preconditioning; prevent; professor; public health relevance; receptor; response; sensor; skills; tool; vascular bed; vasoconstriction; voltage

DESCRIPTION (provided by applicant): Two-pore-domain K+channels (K2P-channels) represent targets for actions of inhalation anesthetics on neurons. The few reports characterizing K2P channels in vascular beds are from pulmonary and mesenteric arteries. We have recently found that ATP stimulates K+current that is resistant to major K+channel blockers and sensitive to pH and Zn. Furthermore, our preliminary data suggest that this current is through K2P channels and that these channels may regulate vessel diameter. This is a novel finding that positions K2P channels as potential targets of inhalation anesthetics in cerebral arteries. Our overall working hypothesis is that volatile anesthetics activate K2P channels in vascular myocytes and thereby dilate arteries. Inhalation anesthetics will activate K2P channels depending on their open probability. Using a combination of electrophysiological, pharmacological, imaging and vessel tension measurements, we will test this hypothesis in the following specific aims. Specific Aim 1: To determine pharmacology of blockers-resistive K2P-like currents in thoracic aorta and middle cerebral artery. In this aim, we propose to prove by pharmacological tools that blockers resistive whole cell outward current inhibited by acidic and stimulated basic pH has K+selectivity and is carried by K2P-like channels. 1) Do known K2P-channel blockers decrease amplitude of leak K+currents in myocytes isolated from thoracic aorta and middle cerebral artery? 2) What part of the resting membrane potential is determined by opening of K2P-like channels in vascular myocytes? 3) What is the impact of K2P channel blockers on vessel diameter? Specific Aim 2: To determine how inhalation anesthetics activate K2P-like channels and the impact of inhalation anesthetics on vascular tone? We will use a combination of electrophysiology, pharmacology, and vessel tension measurements to answer the questions: 1) Do general anesthetics increase the amplitude of K2P channel currents? 2) What is the impact of K2P channel activation by general anesthetics on vessel diameter? 3) Can inhalational anesthetics potentiate ATP-elicited vascular responses? The results of these studies will describe a novel signaling pathway regulating vascular tone through K2P channels. Pharmacological characterization of region specific K2P channels should lead to new targeted treatments of hypertension and stroke and will be of benefit for general anesthesia. PUBLIC HEALTH RELEVANCE: Cardiovascular disease, hypertension and stroke are leading causes of death in the U.S. The present proposal will investigate a novel signaling pathway to regulate vascular tone via K2P channels. Pharmacological characterization of region specific K2P channels (middle cerebral artery and aorta) should lead to new targeted treatments of hypertension and stroke. These types of studies will validate cellular mechanisms of anesthetic action and could be used to develop a possible treatment protocol.

描述（由申请人提供）：双孔结构域K+通道（K2P通道）代表吸入麻醉剂对神经元作用的靶点。少数报道表征血管床中的K2P通道来自肺动脉和肠系膜动脉。我们最近发现ATP刺激的K+电流对主要的K+通道阻断剂有抗性，对pH和Zn敏感。此外，我们的初步数据表明，这种电流是通过K2P通道，这些通道可以调节血管直径。这是一个新的发现，定位K2P通道作为吸入麻醉剂在脑动脉中的潜在目标。我们的总体工作假设是，挥发性麻醉剂激活血管肌细胞中的K2P通道，从而扩张动脉。吸入麻醉剂将激活K2P通道，这取决于它们的开放概率。使用电生理学、药理学、成像和血管张力测量的组合，我们将在以下特定目标中检验这一假设。 具体目的1：确定胸主动脉和大脑中动脉中阻滞剂抵抗性K2P样电流的药理学。在这个目标中，我们建议通过药理学工具证明，阻断剂电阻性全细胞外向电流抑制酸性和刺激的碱性pH值具有K+的选择性，并进行K2P样通道。1)已知的K2P通道阻断剂是否降低了从胸主动脉和大脑中动脉分离的心肌细胞的漏钾电流幅度？2)静息膜电位的哪一部分是由血管肌细胞中K2P样通道的开放决定的？3)K2P通道阻滞剂对血管直径有何影响？ 具体目标2：确定吸入麻醉剂如何激活K2P样通道以及吸入麻醉剂对血管张力的影响？我们将结合电生理学、药理学和血管张力测量来回答以下问题：1）全身麻醉剂是否增加K2P通道电流的幅度？2)全身麻醉药激活K2P通道对血管直径有何影响？3)吸入麻醉药能增强ATP诱导的血管反应吗？这些研究的结果将描述一个新的信号通路调节血管紧张性通过K2P通道。区域特异性K2P通道的药理学特征将导致高血压和中风的新靶向治疗，并将有利于全身麻醉。 公共卫生相关性：心血管疾病、高血压和中风是美国人死亡的主要原因。本提案将研究一种新的信号通路，通过K2P通道调节血管紧张度。区域特异性K2P通道（大脑中动脉和主动脉）的药理学特征应导致高血压和中风的新靶向治疗。这些类型的研究将验证麻醉作用的细胞机制，并可用于开发可能的治疗方案。